Propentofylline: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
No edit summary
 
No edit summary
Line 3: Line 3:
| verifiedrevid = 447813620
| verifiedrevid = 447813620
| IUPAC_name = 3-methyl-1-(5-oxohexyl)-7-propyl-3,7-dihydro-1''H''-purine-2,6-dione
| IUPAC_name = 3-methyl-1-(5-oxohexyl)-7-propyl-3,7-dihydro-1''H''-purine-2,6-dione
| image = Propentofylline.svg
| image = Propentofylline.png


<!--Clinical data-->
<!--Clinical data-->
Line 46: Line 46:
It is a [[phosphodiesterase inhibitor]].<ref name="pmid12804440">{{cite journal |author=Frampton M, Harvey RJ, Kirchner V |title=Propentofylline for dementia |journal=Cochrane Database Syst Rev |volume= |issue=2 |pages=CD002853 |year=2003 |pmid=12804440 |doi=10.1002/14651858.CD002853 |editor1-last=Frampton |editor1-first=Maria A}}</ref>
It is a [[phosphodiesterase inhibitor]].<ref name="pmid12804440">{{cite journal |author=Frampton M, Harvey RJ, Kirchner V |title=Propentofylline for dementia |journal=Cochrane Database Syst Rev |volume= |issue=2 |pages=CD002853 |year=2003 |pmid=12804440 |doi=10.1002/14651858.CD002853 |editor1-last=Frampton |editor1-first=Maria A}}</ref>


It also acts as an [[adenosine reuptake inhibitor]].<ref name="pmid12804440">{{cite journal |author=Frampton M, Harvey RJ, Kirchner V |title=Propentofylline for dementia |journal=[[Cochrane Database Syst Rev]] |volume= |issue=2 |pages=CD002853 |year=2003 |pmid=12804440 |doi=10.1002/14651858.CD002853 |editor1-last=Frampton |editor1-first=Maria A}}</ref><ref name="pmid18096287">{{cite journal |author=Salimi S |title=A placebo controlled study of the propentofylline added to risperidone in chronic schizophrenia |journal=Prog. Neuropsychopharmacol. Biol. Psychiatry |volume=32 |issue=3 |pages=726–732 |date=April 2008 |pmid=18096287 |doi=10.1016/j.pnpbp.2007.11.021 |url=http://linkinghub.elsevier.com/retrieve/pii/S0278-5846(07)00411-3 |author-separator=, |author2=Fotouhi A |author3=Ghoreishi A |display-authors=3 |last4=Derakhshan |first4=M |last5=Khodaieardakani |first5=M |last6=Mohammadi |first6=M |last7=Noorbala |first7=A |last8=Ahmadiabhari |first8=S |last9=Hajiazim |first9=M}}</ref><ref name="pmid9578400">{{cite journal |author=Numagami Y, Marro PJ, Mishra OP, Delivoria-Papadopoulos M |title=Effect of propentofylline on free radical generation during cerebral hypoxia in the newborn piglet |journal=Neuroscience |volume=84 |issue=4 |pages=1127–1133 |date=June 1998 |pmid=9578400 |doi= 10.1016/S0306-4522(97)00542-3|url=http://linkinghub.elsevier.com/retrieve/pii/S0306-4522(97)00542-3}}</ref>
It also acts as an adenosine reuptake inhibitor.<ref name="pmid12804440">{{cite journal |author=Frampton M, Harvey RJ, Kirchner V |title=Propentofylline for dementia |journal=[[Cochrane Database Syst Rev]] |volume= |issue=2 |pages=CD002853 |year=2003 |pmid=12804440 |doi=10.1002/14651858.CD002853 |editor1-last=Frampton |editor1-first=Maria A}}</ref><ref name="pmid18096287">{{cite journal |author=Salimi S |title=A placebo controlled study of the propentofylline added to risperidone in chronic schizophrenia |journal=Prog. Neuropsychopharmacol. Biol. Psychiatry |volume=32 |issue=3 |pages=726–732 |date=April 2008 |pmid=18096287 |doi=10.1016/j.pnpbp.2007.11.021 |url=http://linkinghub.elsevier.com/retrieve/pii/S0278-5846(07)00411-3 |author-separator=, |author2=Fotouhi A |author3=Ghoreishi A |display-authors=3 |last4=Derakhshan |first4=M |last5=Khodaieardakani |first5=M |last6=Mohammadi |first6=M |last7=Noorbala |first7=A |last8=Ahmadiabhari |first8=S |last9=Hajiazim |first9=M}}</ref><ref name="pmid9578400">{{cite journal |author=Numagami Y, Marro PJ, Mishra OP, Delivoria-Papadopoulos M |title=Effect of propentofylline on free radical generation during cerebral hypoxia in the newborn piglet |journal=Neuroscience |volume=84 |issue=4 |pages=1127–1133 |date=June 1998 |pmid=9578400 |doi= 10.1016/S0306-4522(97)00542-3|url=http://linkinghub.elsevier.com/retrieve/pii/S0306-4522(97)00542-3}}</ref>


==Uses==
==Uses==

Revision as of 18:22, 23 July 2014

Propentofylline
Clinical data
AHFS/Drugs.comInternational Drug Names
ATC code
Identifiers
CAS Number
PubChem CID
UNII
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC15H22N4O3
Molar mass306.360 g/mol
  (verify)

Propentofylline (HWA 285) is a xanthine derivative with purported neuroprotective effects.

Pharmacology

It is a phosphodiesterase inhibitor.[1]

It also acts as an adenosine reuptake inhibitor.[1][2][3]

Uses

It was studied as a possible treatment for Alzheimer's disease and multi-infarct dementia.[4][5]

Propentofylline has also been studied, to a lesser extent, as a possible adjunct in the treatment of ischemic stroke, due to its vasodilating properties.[6][7]

Propentofylline is in use in veterinary medicine as a geriatric preparation for old dogs.

See also

References

  1. ↑ 1.0 1.1 Frampton M, Harvey RJ, Kirchner V (2003). Frampton, Maria A, ed. "Propentofylline for dementia". Cochrane Database Syst Rev (2): CD002853. doi:10.1002/14651858.CD002853. PMID 12804440.
  2. ↑ Salimi S; Fotouhi A; Ghoreishi A; et al. (April 2008). "A placebo controlled study of the propentofylline added to risperidone in chronic schizophrenia". Prog. Neuropsychopharmacol. Biol. Psychiatry. 32 (3): 726–732. doi:10.1016/j.pnpbp.2007.11.021. PMID 18096287. Unknown parameter |author-separator= ignored (help)
  3. ↑ Numagami Y, Marro PJ, Mishra OP, Delivoria-Papadopoulos M (June 1998). "Effect of propentofylline on free radical generation during cerebral hypoxia in the newborn piglet". Neuroscience. 84 (4): 1127–1133. doi:10.1016/S0306-4522(97)00542-3. PMID 9578400.
  4. ↑ Frampton M, Harvey RJ, Kirchner V (2003). Frampton, Maria A, ed. "Propentofylline for dementia". Cochrane database of systematic reviews (Online) (2): CD002853. doi:10.1002/14651858.CD002853. PMID 12804440.
  5. ↑ Kittner B, Rössner M, Rother M (1997). "Clinical trials in dementia with propentofylline". Ann. N. Y. Acad. Sci. 826: 307–316. doi:10.1111/j.1749-6632.1997.tb48481.x. PMID 9329701.
  6. ↑ Bath PM, Bath-Hextall FJ (2004). Bath, Philip MW, ed. "Pentoxifylline, propentofylline and pentifylline for acute ischaemic stroke". Cochrane database of systematic reviews (Online) (3): CD000162. doi:10.1002/14651858.CD000162.pub2. PMID 15266424.
  7. ↑ Huber M, Kittner B, Hojer C, Fink GR, Neveling M, Heiss WD (1993). "Effect of propentofylline on regional cerebral glucose metabolism in acute ischemic stroke". J. Cereb. Blood Flow Metab. 13 (3): 526–30. doi:10.1038/jcbfm.1993.68. PMID 8478410.

Template:Phosphodiesterase inhibitors

Retrieved from "https://www.wikidoc.org/index.php?title=Propentofylline&oldid=999716"